Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 9/20 | 0.85 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.85 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.85 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.85 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.85 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.85 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.85 |
| ▸ | GABRP | O00591 | 2/20 | 0.85 |
| ▸ | GABRD | O14764 | 2/20 | 0.85 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.85 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.85 |
| ▸ | GABRE | P78334 | 2/20 | 0.85 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.85 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.85 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.85 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.85 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ro-54864 SCHEMBL29754019 | 1.00 | LMNA (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL9472656 | 0.92 | LMNA (0.85) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL11631556 | 0.92 | LMNA (0.85) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL16922183 | 0.92 | GABRA1 (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL29362687 | 0.92 | GABRA1 (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL21442 | 0.92 | GABRA1 (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL9278054 | 0.92 | GABRA1 (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL1019217 | 0.92 | GABRA1 (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL3043280 | 0.91 | GABRA1 (0.97) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL6014348 | 0.91 | GABRA1 (0.97) | LMNAGAATSPOGABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20240009200-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2024-01-11 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-4240353-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | Imperial College Innovations Limited (GB) | 2023-09-13 | — | — | EP | claimed |
| WO-2022096901-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-12 | — | — | WO | claimed |
| CN-111537628-B | DPX-GC-MS detection method for 2-chlorodiazepam and 4-chlorodiazepam in urine | 无锡微色谱生物科技有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-111537628-A | DPX-GC-MS detection method for 2-chlorodiazepam and 4-chlorodiazepam in urine | 无锡微色谱生物科技有限公司 | 2020-08-14 | — | — | CN | claimed |
| US-20100179133-A1 | COMPOSITIONS, ARTICLES AND METHODS COMRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-07-15 | — | — | US | claimed |
| EP-2170274-A1 | COMPOSITIONS, ARTICLES AND METHODS COMPRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | Technion Research and Development Foundation, Ltd. (IL) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004621-A1 | COMPOSITIONS, ARTICLES AND METHODS COMPRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2009-01-08 | — | — | WO | claimed |
| EP-1839657-A2 | A method for treating vascular headaches | THE GENERAL HOSPITAL CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| US-4898861-A | ADMINISTERING BENZODIAZEPINE COMPOUNDS, SELECTIVE AFFINITY FOR BINDING SITES ON CELL | HOFFMANN-LA ROCHE INC. (US) | 1990-02-06 | — | — | US | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| CN-121287718-A | Use of Ro5-4864 or a pharmaceutically acceptable salt in the manufacture of a medicament for the treatment and/or prophylaxis of melanocyte depletion disorders resulting from oxidative stress induced inflammatory immune responses | 常州大学 | 2026-01-09 | — | — | CN | disclosed |
| CN-121287718-A | Use of Ro5-4864 or a pharmaceutically acceptable salt in the manufacture of a medicament for the treatment and/or prophylaxis of melanocyte depletion disorders resulting from oxidative stress induced inflammatory immune responses | 常州大学 | 2026-01-09 | — | — | CN | disclosed |
| EP-0455805-A4 | A METHOD OF STIMULATING STEROIDOGENESIS WITH ALPIDEM | — | 1992-05-06 | — | — | EP | disclosed |
| US-4898861-A | ADMINISTERING BENZODIAZEPINE COMPOUNDS, SELECTIVE AFFINITY FOR BINDING SITES ON CELL | HOFFMANN-LA ROCHE INC. (US) | 1990-02-06 | — | — | US | disclosed |
| US-4711890-A | TREATMENT OF ANXIETY STATES OR OF PULMONARY, RENAL, CIRCULATORY OF CARDIOVASCULAR DISORDERS | RHONE-POULENC SANTE (FR) | 1987-12-08 | — | — | US | disclosed |
| US-4684652-A | TREATING ANXIETY OR CARDIOVASCULAR DISORDERS | RHONE-POULENC SANTE (FR) | 1987-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | LMNA 757/4885GAA 4002/4885TSPO 2472/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | LMNA 1243/4885GAA 3170/4885TSPO 1395/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | LMNA 1593/4885GAA 681/4885TSPO 1014/4885 |
| US-20100179133-A1 | COMPOSITIONS, ARTICLES AND METHODS COMRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | TACR2, TSPO, GABRB3 | LMNA 987/4885GAA 2097/4885TSPO 2/4885 |
| US-20240009200-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | TSPO, SLC8B1, EDNRB | LMNA 1472/4885GAA 3601/4885TSPO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.